Recent News

• 03.27.2026 - Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
• 03.13.2026 - CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
• 03.09.2026 - Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
• 03.05.2026 - Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
• 02.12.2026 - Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
• 02.12.2026 - Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
• 02.05.2026 - PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

Recent Filings

• 03.13.2026 - 8-K Current report
• 03.13.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 8-K Current report
• 03.09.2026 - 8-K Current report
• 03.09.2026 - EX-99.1 EX-99.1
• 03.05.2026 - EX-99.1 EX-99.1
• 03.05.2026 - 8-K Current report
• 03.05.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.12.2026 - EX-99.1 EX-99.1
• 02.12.2026 - EX-99.1 EX-99.1